TYSABRI

This brand name is authorized in Austria, Australia, Brazil, Canada, Cyprus, Estonia, Spain, Finland, France, Hong Kong, Ireland, Israel, Japan, Lithuania, Netherlands, New Zealand, Poland, Romania, Singapore, Tunisia, Turkey, United Kingdom, United States, South Africa

Active ingredients

The drug TYSABRI contains one active pharmaceutical ingredient (API):

1 Natalizumab UNII 3JB47N2Q2P - NATALIZUMAB

Natalizumab is a selective adhesion-molecule inhibitor and binds to the α4-subunit of human integrins, which is highly expressed on the surface of all leukocytes, with the exception of neutrophils. Read about Natalizumab

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
TYSABRI Concentrate for solution for infusion	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L04AG03	Natalizumab	L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AG Monoclonal antibodies
Discover more medicines within L04AG03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 9505G, 9624M
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 538300201159311
Country: CA	Health Products and Food Branch	Identifier(s): 02286386
Country: EE	Ravimiamet	Identifier(s): 1250840, 1843882
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 06346001
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 056915, 069394
Country: FR	Base de données publique des médicaments	Identifier(s): 68722564
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 106264, 396511
Country: HK	Department of Health Drug Office	Identifier(s): 61519
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 6128
Country: JP	医薬品医療機器総合機構	Identifier(s): 1190402A1028
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1031485, 1075654, 1092352
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 80934
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 12660
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100003952, 100450520
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W65148001, W67544001
Country: SG	Health Sciences Authority	Identifier(s): 14408P
Country: TN	Direction de la Pharmacie et du Médicament	Identifier(s): 10913041H
Country: TR	İlaç ve Tıbbi Cihaz Kurumu	Identifier(s): 8699783760014
Country: US	FDA, National Drug Code	Identifier(s): 64406-008
Country: ZA	Health Products Regulatory Authority	Identifier(s): 42/30.1/0765